<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04444440</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00101838</org_study_id>
    <nct_id>NCT04444440</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis for Bladder Botox</brief_title>
  <official_title>Prophylactic Antibiotics During Treatment of Idiopathic Overactive Bladder With Intradetrusor onabotulinumtoxinA for the Reduction of Postoperative UTI: a Randomized Blinded Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Women and Children's Health Research Institute, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Injection of Botox into the bladder is a common treatment for overactive bladder.&#xD;
      Postoperative bladder infection is one of the more frequently reported complications of this&#xD;
      procedure. Prophylactic antibiotics given at the time of bladder Botox for the reduction of&#xD;
      postoperative bladder infection have not been well studied. The main goal of our study is to&#xD;
      determine if prophylactic antibiotics at the time of bladder Botox injection for the&#xD;
      treatment of overactive bladder in women reduces postoperative bladder infection. The&#xD;
      investigators are proposing a study which will randomize participants into two groups - one&#xD;
      receiving Ciprofloxacin and the other receiving placebo pills for three days following the&#xD;
      procedure. The primary outcome evaluated will be the difference in postoperative bladder&#xD;
      infection between the two groups. The investigators will also investigate differences in&#xD;
      reported side effects between the two groups possibly related to antibiotic use. Follow-up&#xD;
      will be over six weeks following the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a single-centred, double-blinded, randomized, placebo-controlled trial.&#xD;
      Recruitment will be undertaken at two Urogynecology/Urology sites associated with the&#xD;
      University of Alberta in Edmonton, Alberta. Participants will be randomized to treatment or&#xD;
      placebo arm with a 1:1 allocation ratio. Patients and surgeons will be blinded.&#xD;
&#xD;
      On the day of the procedure, a urine culture will be collected preoperatively to identify&#xD;
      pre-existing bacteriuria. Technique and dose of Botox injection will be at the discretion of&#xD;
      the operating physician. Trigone-sparing technique with injection of 100 to 200 units of&#xD;
      Botox distributed across 10 to 20 sites is generally used at our centre.&#xD;
&#xD;
      Follow-up will occur over a six-week postoperative period. A questionnaire will be used at&#xD;
      each follow-up encounter to screen patients for urinary tract infection symptoms, voiding&#xD;
      dysfunction, and other adverse events potentially related to the prophylactic antibiotics.&#xD;
      Urine cultures will be collected to confirm infection for patients developing postoperative&#xD;
      symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized at a 1:1 allocation ratio to two parallel treatment arms - intervention versus placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Postoperative Urinary Tract Infection</measure>
    <time_frame>2 weeks following the procedure</time_frame>
    <description>new or worsening symptoms (dysuria, hematuria, frequency, urgency, suprapubic/flank pain, fever) AND positive urine culture (&gt;10^5 CFU/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Postoperative Urinary Tract Infection Rate</measure>
    <time_frame>1 and 6 weeks following the procedure</time_frame>
    <description>new or worsening symptoms (dysuria, hematuria, frequency, urgency, suprapubic/flank pain, fever) AND positive urine culture (&gt;10^5 CFU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Other Adverse Events</measure>
    <time_frame>1, 2 and 6 weeks following the procedure</time_frame>
    <description>New onset of side effects possibly related to Ciprofloxacin (nausea/vomiting, headache, abdominal pain, constipation, diarrhea, other)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Idiopathic Overactive Bladder</condition>
  <condition>Postoperative Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin 500 mg PO every 12 hrs for 3 days following the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill PO every 12 hrs for 3 days following the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Fluoroquinolone antibiotic.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Pill</intervention_name>
    <description>Placebo Pill</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with idiopathic OAB diagnosed clinically who have failed medical management&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with neurogenic OAB (OAB with potential underlying neurologic cause -&#xD;
             multiple sclerosis, spinal cord injury, Parkinson's disease, other)&#xD;
&#xD;
          -  Contraindication to injection of Botox - hypersensitivity to any botulinum toxin&#xD;
             preparation or to any of the components in the formulation, current urinary tract&#xD;
             infection, symptomatic urinary retention or PVR &gt; 200 mL, unwillingness or inability&#xD;
             to initiate CIC post-treatment if required.&#xD;
&#xD;
          -  Contraindication to oral Ciprofloxacin - hypersensitivity or allergy to Ciprofloxacin&#xD;
             or other fluoroquinolone, concurrently taking Tizanidine or Agomelatine.14&#xD;
&#xD;
          -  Active antibiotic therapy for any indication at the time of Botox injection -&#xD;
             increased risk of adverse reaction with combining antibiotics, reduced risk of UTI&#xD;
             with additional antibiotic.&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Pregnant and/or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erin Kelly, MD FRCSC</last_name>
    <phone>780-735-5290</phone>
    <email>eckelly@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Schulz, MR FRCSC</last_name>
    <phone>780-970-4659</phone>
    <email>schulz@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urogynecology Clinic - Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Kelly, MD FRCSC</last_name>
      <phone>7807355290</phone>
      <email>eckelly@ualberta.ca</email>
    </contact>
    <contact_backup>
      <last_name>Paul Groves, MD FRCSC</last_name>
      <phone>7809991561</phone>
      <email>pgroves@ualberta.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Erin Kelly, MD FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Schulz, MD FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Groves, MD FRCSC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

